Alnylam Pharmaceuticals Inc.  (ALNY) Trade Now »     Rate ALNY  -  Discuss ALNY  -  Add to Watch List        

Home

Analysis & Videos

Quotes

Bull or Bear

Discuss

ALNY Analysis & Videos »


ALNY: Bull or Bear?

FDA, Clinical Trial Calendar Updates: THRX, GILD, TEVA, ALNY, RNUGF ALNY

73%

-8.35% in 220 days Below is a summary of updates to the BioMedReports.com database of 239 entries included in the FDA and Clinical Trial Calendars .    The FDA Calendar includes companies with pending new drug, biological agent, or medical device new product decisions at the FDA sorted by their PDUFA deadline dates. The entries are updated on a daily basis as new information becomes available with a total of 112 entries through 4/6/09. The FDA Calendar includes the following information: company name, ticker, decision date, and description.     <> The Clinical Trial Calen... Continue reading »

By  Mike Havrilla   (+1.04%  risk: conservative)  04/06/09

Comment

Trading the Trials and FDA Decision Calendar ALNY

73%

-13.67% in 72 days (closed on 04/06/09) Trading the Trials and FDA Decision Calendar   The tables at my website links below feature an updated calendar of 80 expected FDA new product decisions and 89 pending clinical trial result estimates + pending FDA re-submissions. Click here for a link to my previous FDA calendars and click here for a list of 14 extreme trades of companies with market caps below $100M and pending new drug decisions at the FDA.   http://www.etfinnovators.com/2009/01/trading-trials-and-fda-d...   <> Below is a summary of the major updates on the calendar... Continue reading »

By  Mike Havrilla   (+1.04%  risk: conservative)  01/24/09

Comment

Emerging Biotech & Pharma Index: 36 More Companies ALNY

73%

+19.09% in 61 days (closed on 01/24/09) Emerging Biotech & Pharma Index: 36 More Cos. <> The accompanying table [click to enlarge or download] includes the 36 remaining companies in the ETF Innovators [ETFI] Emerging Bio-Pharma Index with market caps between $150M-$1.5B, which were not included in the previous two articles I wrote about the group – featuring the Top 40 Rated Companies and companies below the $150M market cap cutoff. However, several of the companies included in the remaining group of 36 have been in the news recently due to FDA related news . Late last week, Ligand Phar... Continue reading »

By  Mike Havrilla   (+1.04%  risk: conservative)  11/23/08

Comment

Biotech Blues: Four Stocks on Sale with Hope ALNY

73%

-9.33% in 29 days (closed on 11/23/08) Biotech Blues: Four Stocks on Sale with Hope <> The following group of biotech companies have market caps of at least $300M with a one year stock price change that is below the iShares Nasdaq Biotech ETF (IBB) loss of 21.8% (Source: Google Finance, 10/25/08) with potential upside catalysts over the next year. Alnylam Pharma (ALNY): $872M, -31.6% Biogen Idec (BIIB): $12B, -48.4% BioMarin Pharma (BMRN): $1.7B, -33% Momenta Pharma (MNTA): $348M, -23.4% Momenta and Novartis (NVS) expect to launch a generic version (M-Enoxaparin) of the injectable... Continue reading »

By  Mike Havrilla   (+1.04%  risk: conservative)  10/25/08

Comment

Who's Next in the Biotech Buyout Frenzy? ALNY

73%

-17.90% in 12 days (closed on 10/25/08) Who's Next in the Biotech Buyout Frenzy? <> The biotech industry is rapidly consolidating as big pharma companies put their cash stash to use in deals ranging from well-known large caps all the way down to unknown micro-caps in an effort to bolster their range of marketed products, late stage pipeline candidates, and drug discovery technology platforms. Genentech (DNA) has rejected Roche's (RHHBY) $89 bid to acquire the remaining 44% of DNA it does not already own as insufficient. I think DNA could easily get $100 per share based on Eli Lilly's (LLY) $70 buyout of ImClo... Continue reading »

By  Mike Havrilla   (+1.04%  risk: conservative)  10/13/08

Comment

Mergers for Alnylam Create Risk ALNY

-40.52% in 530 days After signing a multi-million dollar deal with Roche in 2007, the company has continued the deal-signing spree. Continue reading »

By  Zacks.com   (-14.21%  risk: moderate)  05/30/08

Comment

Long on RNAi Science ALNY

N/A

-27.08% in 848 days RNAi is a great technology that will create a great drug pipeline.  Alnylam is at the forefront, as is Sirna, which I would have bought had I done my proper research and Merck beat me to the punch with an acquisiton. The risk here is classic biotech risk - can they actually produce working/approvable therapeutics and how much cash will it take to get them there? This is a long-term hold - ALNY will have volatility, but is an option with tons of upside at the end of the day. Continue reading »

By  benc   (-27.07%  risk: aggressive)  07/17/07

Comment

RNAi has potential ALNY

32%

-19.01% in 1010 days Merck bought Sirna Therapeutics for the potential of RNAi to become an entirely new class of drug.  Alnylam has many partnerships (Novartis, Merck, Medtronic) to share the burden of drug discovery and development.  A recent follow-on stock offering has brought them to a cash balance of greater than $200M.  They only plan to burn about $35M in 2007, so they will be viable for quite a long time even if they face setbacks.  More compounds should enter clinical trials this year for various diseases and conditions, including Pandemic flu. Continue reading »

By  Michael   (+1.10%  risk: aggressive)  02/05/07

Comment

People Bullish on ALNY

Mike Havrilla Principal 73% 7 mos ago	benc Analyst N/A over 2 years ago	Perry C Analyst N/A over 2 years ago
chuchogold Analyst 28% over 2 years ago	Michael Associate 32% over 2 years ago

People Bearish on ALNY

... more »  

None of the information contained on SocialPicks.com constitutes a recommendation by SocialPicks or its users that any particular security, portfolio of securities, transaction, or investment strategy is suitable for any specific person. SocialPicks is not responsible for the posts, discussions, and recommendations of the users on the Site. SocialPicks does not provide investment advice. You must make your own independent decisions regarding any security, portfolio of securities, transaction, or investment strategy mentioned on the website. SocialPicks' users' past results are not necessarily indicative of future performance. Neither SocialPicks nor any of its users guarantees any specific outcome or profit, and you should be aware of the real risk of loss in following any strategy or investments discussed on the website. You understand and agree that you use the Site and Services at your own discretion and risk and that you will be solely responsible for any damages that arise from such use. Before acting on any information contained on the website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.